{"entity":{"id":"nct07669467","kind":"trial","name":"Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer","aka":[],"tldr":"A phase 3 trial of Nuvastatic 300 in triple-negative breast cancer, run by Natureceuticals Sdn Bhd, now recruiting.","summary":"Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer is a phase 3 interventional study registered as NCT07669467 by Natureceuticals Sdn Bhd, with 250 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: Nuvastatic 300 and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07669467","url":"https://clinicaltrials.gov/study/NCT07669467"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07669467","phase":"3","setting":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300 mg Capsules in Reducing Chemotherapy-Induced Fatigue in Patients With Metastatic Triple-Negative Breast Cancer Receiving Standard Chemotherapy","sponsor":"Natureceuticals Sdn Bhd","enrolled":250,"outcomes":[]},"route":"/trials/nct07669467/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}]}}